Christopher Cannon: Discontinuation vs. Continuation of Statin Therapy in Adults Aged Under 75
Christopher Cannon, Cardiologist at Brigham and Women’s Hospital, Editor-in-Chief of Harvard Heart Letter, shared a post on LinkedIn about a recent article by Fabrice Bonnet, published in The Lancet Healthy Longevity, adding:
“Small randomized trial of stopping statins vs continuing in the elderly (low than 75) showed no diff in mortality but the expected trends for higher risk (about 20-30% higher) for MI stroke and MACE events).
No quality of life benefit for ‘deprescribing’.
So – best to keep the statin going!”
Title: Discontinuation of statins for primary prevention of atherosclerotic cardiovascular disease in adults aged 75 years or older (SAGA/SITE): a multicentre, open-label, pragmatic, non-inferiority randomised trial
Authors: Fabrice Bonnet, Pierre Poulizac, Nicolas Rousselot, Thierry Couffinhal, Gaël Galli, Driss Berdaï, Marie-Anne Vandenhende, Marine Rousset, Roxane Coueron, Antoine Bénard, Jean-Philippe Joseph
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 2, 2026, 09:20Anticoagulants, Blood Thinners, or Antithrombotic Medications? – World Thrombosis Day
-
Oct 2, 2026, 06:00Susan Wickersham: Gradual Shift towards Autologous Blood Transfusion is a Current Trend
-
Oct 2, 2026, 05:54Shamee Shastry: When Every Cell Reacts – The Hunt for Rare Blood
-
Oct 2, 2026, 05:49David Mclntosh: Expanding Plasma Protein Therapies in Underserved Regions
-
Oct 2, 2026, 05:38Dianne E. van der Wal: C-Terminal Endings Impact PAR1/PAR4 Peptide Potency in In Vitro Platelet Assays
-
Oct 2, 2026, 05:29Mohammed Alo: Your LDL Isn’t a Snapshot – It’s a Smoking Habit Measured in Years
-
Oct 2, 2026, 00:33Marwa Mostafa: Hemoglobinopathies – When Globin Genes Go Wrong
-
Oct 1, 2026, 23:46Behnood Bikdeli: Global Burden of Venous Thromboembolism
-
Oct 1, 2026, 23:46Sthanu Subramanian: Clinical Presentation, Risk Factors, Diagnosis, and Neuroimaging Findings in CVT